What Are The Purported Benefits Of Survodutide (6mg)?
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist engineered to address metabolic disorders through dual energy regulation pathways. Clinical evidence from Phase 2 trials demonstrates dose-dependent efficacy.
Substantial Weight Reduction
In Phase 2 obesity trials spanning 46 weeks, survodutide 4.8 mg produced mean weight loss of approximately 14.9%, significantly exceeding placebo (2.8%). Notably, 55% of participants achieved ≥15% weight loss, with responses continuing throughout the study period without early plateau. Across all tested doses, the 4.8 mg formulation demonstrated superior weight-loss outcomes compared to the 6.0 mg dose, establishing a clear dose-response ceiling.
MASH Improvement and Liver Fat Reduction
In adults with metabolic dysfunction–associated steatohepatitis (MASH), survodutide demonstrated substantial hepatic benefits over 48 weeks:
- MASH improvement (no fibrosis worsening): 47% (2.4 mg), 62% (4.8 mg), 43% (6.0 mg) vs. 14% placebo
- Liver fat reduction ≥30%: 63% (2.4 mg), 67% (4.8 mg), 57% (6.0 mg) vs. 14% placebo
- Fibrosis improvement ≥1 stage: 34–36% across doses vs. 22% placebo
The 4.8 mg dose consistently outperformed the higher 6.0 mg dose on primary endpoints, supporting this as the therapeutic optimum.
Glycemic Control
In individuals with type 2 diabetes, survodutide demonstrated dose-dependent HbA1c reductions aligning with weight-loss improvements, offering dual metabolic benefit for those with coexisting obesity or liver disease.
What Is The Chemical Makeup Of Survodutide (6mg)?
Survodutide (chemical designation BI 456906) is a synthetic, long-acting peptide optimized for once-weekly subcutaneous administration.
- CAS: 2805997-46-8
- Chemical Formula: C₁₉₂H₂₈₉N₄₇O₆₁
- Molecular Weight: 4231.63 g/mol
- Peptide Sequence: His-{1-Aminocyclobutanecarboxylic acid}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-{Lys(Gly-Ser-Gly-Ser-Gly-Gly-γGlu-C18 diacid)}-Trp-Leu-Glu-Ser-Ala-NH2
Mechanism of Action
The C18 fatty-acid conjugation promotes reversible albumin binding, prolonging circulation and reducing enzymatic degradation. This design enables once-weekly dosing with predictable pharmacokinetics.
- GLP-1 receptor activation: appetite suppression, slower gastric emptying, improved glucose homeostasis
- Glucagon receptor activation: increased hepatic energy expenditure, enhanced hepatic lipid oxidation
This dual mechanism differentiates survodutide from single-pathway therapies, providing synergistic effects on both energy intake and expenditure.
What Does Scientific Research Say About Survodutide (6mg)?
Phase 2 studies describe Survodutide as a potent metabolic agent with clear dose–response relationships and a characteristic incretin-like safety profile.
Dose–Response Relationship
Phase 2 data establish clear dose-dependent efficacy with an optimal therapeutic window. The 4.8 mg dose delivered the highest response rates on primary endpoints for both obesity and MASH, while the 6.0 mg dose showed lower efficacy and higher adverse-event discontinuation rates—indicating a plateau or decline in the benefit-risk ratio at higher exposures.
Safety and Tolerability
Gastrointestinal adverse events are the primary tolerability concern, dose-related and consistent with other incretin-based therapies:
- Nausea: ~66% vs. 23% placebo
- Diarrhea: ~49% vs. 23% placebo
- Vomiting: ~41% vs. 4% placebo
Treatment discontinuation due to adverse events occurred in approximately 20% of survodutide-treated participants (predominantly GI-related), compared with 3% on placebo. Clinical protocols employ gradual dose escalation to improve real-world tolerability.
Clinical Development Status
Survodutide is currently being evaluated in the Phase 3 SYNCHRONIZE program across obesity, MASH, liver fibrosis, and metabolic disorders. Phase 3 dose selection prioritizes the 4.8 mg dose based on Phase 2 risk-benefit analysis. The survodutide peptide remains investigational and is not approved for routine clinical use.
What Are The Storage Conditions For Survodutide (6mg)?
For routine handling, keep vials at 2–8 °C and return them promptly after each use to reduce total room-temperature exposure time. For long-term retention, store at <=–20 °C and avoid unnecessary temperature cycling (repeated warm/cool transitions). Protect from light during storage and handling (e.g., keep vials in original packaging or a light-blocking container) to reduce light-driven degradation risk.
Are you looking to buy Survodutide (6mg) online?
If you’re looking to order Survodutide (6mg) online at wholesale prices, contact Medical Spa RX for guidance on how to do so.
This product is supplied strictly for laboratory research use only and is not approved for human or veterinary administration. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines. By purchasing or using this material, the buyer confirms that they are a qualified researcher and that the product will be used exclusively in controlled research settings compliant with all applicable regulations.
Sources
https://www.jci.org/articles/view/186425
https://pubmed.ncbi.nlm.nih.gov/38847460
https://www.sciencedirect.com/science/article/pii/S2213177924006620
https://pmc.ncbi.nlm.nih.gov/articles/PMC9679702
https://pmc.ncbi.nlm.nih.gov/articles/PMC9679702